Levodopa-induced dyskinesia (LID) is a common complication after dopamine-replacement therapy in Parkinson's disease. The neural mechanisms underlying LID are far from clear, although significant ...

Get detailed information on Levodopa, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s diseaseARISE will ...

Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous 24 ...

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson's disease (PD). Vyalev is the first and only ...